Choosing between semaglutide vs tirzepatide can feel overwhelming. Both are highly effective GLP-1 medications for weight loss and blood sugar control, but they work differently and produce different results. Here's what you need to know to have an informed conversation with your healthcare provider.
Semaglutide vs tirzepatide: which GLP-1 medication is right for you? Compare weight loss results, side effects, dosing, and costs in our comprehensive guide.
Understanding the Basics
Semaglutide (Ozempic, Wegovy, Rybelsus)
Semaglutide is a pure GLP-1 receptor agonist. It mimics one hormone — GLP-1 — to:
- Reduce appetite and food cravings
- Slow gastric emptying
- Improve insulin sensitivity
- Stabilize blood sugar levels
Available as weekly injections (Ozempic, Wegovy) or daily oral tablets (Rybelsus).
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It mimics two hormones — GIP and GLP-1 — which may provide enhanced benefits. Effects include:
- Potent appetite suppression
- Further slowed gastric emptying
- Improved blood sugar control
- Significant weight loss
Available as weekly injections under brand names Mounjaro (diabetes) and Zepbound (weight loss).
Track your labs and see how your protocol moves your biomarkers.
Track it in the appWeight Loss Results: Semaglutide vs Tirzepatide
Semaglutide Clinical Data
Clinical trials for Wegovy (semaglutide 2.4 mg) showed:
- Average weight loss of 14.9% of body weight over 68 weeks
- 50% of participants lost 15% or more of body weight
- 33% of participants lost 20% or more of body weight
Tirzepatide Clinical Data
SURPASS and SURMOUNT trials showed tirzepatide produced:
- Average weight loss of 20-22.5% of body weight over 72 weeks
- 40-63% of participants lost 20% or more of body weight
- More rapid initial weight loss compared to semaglutide
The Bottom Line on Efficacy
In head-to-head comparisons, tirzepatide consistently produces greater weight loss than semaglutide. However, individual responses vary, and both medications represent significant advances over previous treatments.